Collegium Pharmaceutical’s (COLL) “Buy” Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Collegium Pharmaceutical Inc. (NASDAQ:COLL) in a research report sent to investors on Wednesday morning. They currently have a $30.00 price target on the specialty pharmaceutical company’s stock.
Other analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a report on Tuesday, June 28th. Piper Jaffray Cos. restated a buy rating and set a $27.00 price objective (up previously from $26.00) on shares of Collegium Pharmaceutical in a report on Thursday, June 23rd. Finally, Gabelli started coverage on shares of Collegium Pharmaceutical in a report on Tuesday, September 13th. They set a buy rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $27.60.
Collegium Pharmaceutical (NASDAQ:COLL) opened at 10.53 on Wednesday. Collegium Pharmaceutical has a 12 month low of $8.24 and a 12 month high of $30.58. The firm’s market capitalization is $247.75 million. The stock has a 50 day moving average of $10.57 and a 200 day moving average of $14.52.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. On average, equities analysts predict that Collegium Pharmaceutical will post ($3.86) earnings per share for the current fiscal year.
In other news, Director John A. Fallon acquired 2,375 shares of the business’s stock in a transaction dated Friday, August 12th. The stock was bought at an average cost of $10.59 per share, for a total transaction of $25,151.25. Following the completion of the transaction, the director now owns 2,375 shares of the company’s stock, valued at $25,151.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 37.93% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its position in Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares during the period. Schwab Charles Investment Management Inc. purchased a new position in Collegium Pharmaceutical during the second quarter worth approximately $253,000. Highbridge Capital Management LLC purchased a new position in Collegium Pharmaceutical during the second quarter worth approximately $166,000. Sabby Management LLC raised its stake in shares of Collegium Pharmaceutical by 23.5% in the second quarter. Sabby Management LLC now owns 101,410 shares of the specialty pharmaceutical company’s stock valued at $1,202,000 after buying an additional 19,310 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at about $148,000. Institutional investors own 62.13% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.